Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
US 10,899,748 In forceTerm ends Aug 29, 2037 · From the USPTO record
20-year base term ends Jun 19, 2037
Jun 19, 2017
Aug 29, 2037
Jan 26, 2021
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 19, 2017, when this application, 16/308,648, was filed | Jun 19, 2037 | USPTO record |
| Continuity chain | Every parent in the chain resolved | no change | USPTO record |
| Patent term adjustment | +71 days, USPTO patent term adjustment record | Aug 29, 2037 | USPTO record |
| Terminal disclaimer cap | None on record | no cap applied | USPTO record |
| Patent term extension | None on file | no change | USPTO record |
| Fee events | 1 of 3 maintenance fees paid | In force | USPTO record |
| Computed term end | The steps above, in order | Aug 29, 2037 | USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.